Business Context and Reporting Period
Company: Intuitive Surgical, Inc. (ISRG)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2025
Business Overview: Intuitive develops, manufactures, and markets the da Vinci surgical systems and the Ion endoluminal system. The company operates in one reportable segment, focusing on minimally invasive care through robotic-assisted surgery and diagnostic procedures.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $2,253.4 | $1,890.6 |
| Gross Profit | $1,457.7 | $1,245.4 |
| Gross Margin | 64.7% | 65.9% |
| Operating Income | $578.1 | $469.4 |
| Net Income (Attributable to ISRG) | $698.4 | $544.9 |
| Diluted EPS | $1.92 | $1.51 |
| Operating Cash Flow | $581.6 | $265.4 |
| Cash, Equivalents & Investments | $9,101.2 | $8,832.4 |
| Total Debt | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 19% year-over-year, driven by an 18% increase in instruments and accessories revenue and a 25% increase in systems revenue.
- Procedure Volume: da Vinci procedures grew 17% to approximately 732,000, while Ion procedures surged 58% to approximately 30,700.
- System Placements: Total da Vinci system placements rose to 367 (up from 313), with 147 being the new da Vinci 5 systems. Ion placements decreased to 49 from 70 as the U.S. market shifts from capacity building to utilization.
- Margin Compression: Gross margin decreased 120 basis points to 64.7%, primarily due to higher costs associated with the da Vinci 5 launch, increased depreciation from expanded manufacturing capacity, and higher scrap rates.
- Expense Increases: Operating expenses rose 13% to $879.6 million, driven by higher headcount, share-based compensation ($185.2 million vs. $153.3 million), and R&D investments.
Guidance, Outlook, and Risks
- Tariff Impact: While Q1 2025 tariff impacts were immaterial, the company anticipates a significant adverse impact on costs of revenue in the second half of 2025 due to new U.S. tariffs on imports from Mexico, Canada, and China, as well as reciprocal tariffs from China. This is expected to increase costs for raw materials and the da Vinci Xi system in China.
- Capital Expenditures: Management expects 2025 capital expenditures to range between $650 million and $750 million, primarily for facilities to scale manufacturing.
- Product Launches: The company is in a phased launch of the da Vinci 5 system and expanding the da Vinci SP system in Europe and Asia. Regulatory clearances for the da Vinci 5 were obtained in South Korea and the U.S.
- Legal Contingencies: The company faces ongoing product liability lawsuits and antitrust litigation (e.g., SIS, Larkin Community Hospital). While the company disputes allegations, outcomes remain uncertain and could materially affect financial results.
- Macroeconomic Risks: Risks include supply chain disruptions, inflationary pressures, elevated interest rates affecting hospital capital spending, and geopolitical conflicts.
Investor Verification Checklist
- Tariff Exposure: Verify the specific impact of the April 2025 tariff announcements on the cost of goods sold for the da Vinci Xi system in China and raw materials imported from Mexico and Germany.
- da Vinci 5 Adoption: Monitor the conversion rate of da Vinci 5 placements and the associated margin profile as the phased launch continues.
- China Market Dynamics: Assess the impact of the "governance campaign" and domestic competition on system placements and procedure volumes in China.
- Antitrust Litigation: Track the status of the SIS appeal and the class action antitrust litigation regarding instrument repair markets.
- Inventory Levels: Review the $211 million increase in inventory on the cash flow statement to ensure it aligns with demand forecasts and does not signal future obsolescence risks.